Biosimilar approval is not the finish line.
It's the point at which your pre-approval dataset — intentionally smaller than a novel biologic — meets real patients, real clinical practice, and real immune systems.
PMS isn't overhead. It's the second half of your evidence strategy.
#Biosimilars #Pharmacovigilance #ClinicalResearch #Pharma #CRO #CDSCO #ClinicalTrials #genelife
https://genelifecr.blogspot.com/2026/05/post-marketing-surveillance-for.html






